• HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.
• HeartBeam’s technology is aligned with evolving regulatory and clinical priorities.
• In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report.

HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s electrical signals from three distinct directions and synthesize them into a 12-lead ECG for arrhythmia assessment.

The company was included in a report published by Modern Healthcare and authored by Lauren Dubinsky. The report examined recent FDA activity across the medical device landscape, highlighting companies that achieved meaningful regulatory milestones or demonstrated forward momentum entering the new year. HeartBeam was included as part of this broader discussion of innovation and regulatory progress within the sector, reflecting growing attention on technologies aimed at improving access to clinical-grade data outside of traditional healthcare settings.

Being cited in the Modern Healthcare report places HeartBeam alongside other device developers whose products have either secured regulatory clearance or are progressing through the FDA process. The roundup focused on how recent approvals and regulatory decisions may shape the medical device market in the year ahead, particularly as healthcare systems continue to adopt technologies that support decentralization, remote monitoring and earlier intervention. HeartBeam’s mention reflects the relevance of its approach within these broader industry trends.

HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. While many portable cardiac monitoring devices on the market provide limited, single-lead data intended primarily for wellness or screening purposes, HeartBeam is focused on delivering higher-fidelity signals. This emphasis on clinical-grade data helps explain why the company was included in a report centered on FDA activity and medical device innovation, rather than consumer health technology alone.

In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. “HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated,” the company noted in the announcement. The ranking reflects the strength of [HeartBeam’s] intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.

Beyond this recognition, the company continues to build toward its longer-term objective of bringing clinical-grade cardiac insights into more accessible environments. HeartBeam’s core platform, the HeartBeam System, is designed as the first cable-free, high-fidelity ECG system capable of capturing electrical signals from three distinct directions. This multidirectional approach enables a more comprehensive view of cardiac electrical activity than is possible with traditional handheld or wearable ECG devices that rely on a single signal pathway.

The HeartBeam System integrates electrodes into a compact handheld form factor, allowing patients to record ECG signals without adhesive patches, wires or external sensors. By simplifying the recording process while maintaining signal quality, the system is intended to support use in nonclinical settings, including at home or during symptomatic episodes that might otherwise go undocumented.

The inclusion of HeartBeam in the Modern Healthcare FDA roundup also highlights the growing importance of regulatory engagement for emerging medical device companies. Navigating the FDA process is a critical step in translating innovative technology into tools that can be adopted within mainstream healthcare. HeartBeam is working closely with regulators as it advances its platform, positioning the company to participate in a healthcare environment that increasingly values validated, high-quality data delivered beyond traditional care settings.

As the medical device sector enters the new year, attention is increasingly focused on technologies that can expand access to care, improve diagnostic efficiency and support earlier intervention. HeartBeam’s appearance in an industry-wide review of FDA activity reflects its alignment with these priorities. By developing a portable, cable-free ECG system designed to deliver clinically meaningful insights, the company is aiming to address persistent gaps in cardiac monitoring and arrhythmia assessment.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax released Phase 2 stream sediment assay results from its Cameron Rare Earth Element Project in British Columbia, showing elevated light, heavy, and total rare earth oxides, across multiple drainage catchments.
• Results point to potential upstream bedrock sources and define priority areas for follow-up exploration.
• The company plans to integrate these findings with pending soil and rock sample data.
• Powermax is advancing a portfolio of REE assets in Canada and the U.S., including projects in Ontario and Wyoming.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, recently reported new assay results from its Phase 2 stream sediment sampling program at the Cameron Rare Earth Element (“REE”) Project in British Columbia, outlining a series of anomalous rare earth values that management says will help refine exploration targets (https://ibn.fm/Ogebu).

The Toronto-based company said sampling across multiple drainage systems returned elevated light rare earth oxides (“LREO”), heavy rare earth oxides (“HREO”), and total rare earth oxides (“TREO”), reinforcing the effectiveness of stream sediment geochemistry as a tool for identifying REE mineralization. According to Powermax, Phase 2 assay results showed:

• LREO values ranging from 178.6 parts per million (“ppm”) to 47,980.5 ppm
• HREO values from 49.0 ppm to 9,537.3 ppm
• TREO values from 227.7 ppm to 57,517.8 ppm

Several drainage catchments displayed coherent multi-element anomalies, with enrichment in both light and heavy rare earths. The company also reported consistently high eTh/K ratios (greater than 10 in many samples), suggesting the presence of thorium-rich accessory minerals such as monazite or xenotime being transported downstream.

Management said these patterns indicate likely upstream bedrock sources and help define priority zones for follow-up geological mapping, soil sampling, and potential trenching or drill testing, subject to permitting.

“The Phase 2 stream sediment assay results further validate our systematic exploration approach at the Cameron Rare Earth Element Project,” CEO Paul Gorman said. “The broad range of elevated LREO, HREO, and TREO values across multiple drainage catchments highlights the extent and consistency of REE anomalies and confirms stream sediment geochemistry as an effective tool for defining priority target areas.” Gorman added that the company will integrate the new data with soil and rock sample results that are currently being processed.

Sampling for the Phase 2 program focused on active drainage systems. Sediments were sieved to less than 18 mesh and analyzed by AGAT Laboratories in Calgary, an ISO/IEC 17025:2017 accredited facility, using its 201-380 metals package. Powermax said quality control included the insertion of field duplicates. The Cameron REE Project is located in the Kamloops Mining Division of British Columbia and comprises three mineral claims totaling roughly 2,984 hectares. Powermax holds an option to acquire the property.

Beyond Cameron, Powermax is building a broader REE-focused portfolio. The company also holds options on the Atikokan REE Property and the Pinard REE Property in northern Ontario and owns a 100% interest in the Ogden Bear Lodge Project in Crook County, Wyoming.

Powermax positions itself as an early-stage exploration company aiming to identify and define economically viable rare earth deposits in Canada and the United States.

The company’s latest results arrive as rare earth elements continue to draw attention from investors and policymakers alike. Global demand for REEs is projected to rise sharply over the next decade, driven largely by electric vehicle production, wind power deployment, and other clean energy technologies. At the same time, China maintains a dominant role in both mining and processing, prompting efforts in North America to diversify supply chains.

In the United States, federal initiatives such as the Defense Production Act are being used to direct funding toward domestic and allied REE development, including grants and long-term purchase commitments. Canadian companies are eligible for parts of this funding, potentially providing additional support for exploration and downstream processing projects.

For Powermax, the Cameron results represent another technical data point as it works to advance its properties from early-stage exploration toward defined drill targets. While the company remains in the exploration phase, the growing dataset at Cameron is helping narrow the search for potential REE-bearing source rocks.

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage mining company, just added 144 new mining claims in and around its Montauban project in Quebec
• The expansion follows the recent completion of an ANT-based 3D geological model, suggesting the potential for a mineralized corridor extending approximately 900 meters in depth and over two kilometers of strike
• The expansion allows ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, marking a critical inflection point for the company, with evaluation that is no longer constrained by historical evaluations

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just added 144 new mining claims in and around its Montauban project, bringing the total to 417 mining claims. This milestone represents the largest contiguous mineral tenure held by a single company in the region. The move also ensures that the company is not constrained by historical boundaries that previously limited its operations (https://ibn.fm/bXFk9).

The expansion follows the recent completion of an ambient noise tomography (“ANT”)- based 3D geological model, which suggested the potential for a mineralized corridor extending to approximately 900 meters in depth and over 2 kilometers of strike, remaining open beyond the limits of the existing survey area at the property.

“The recently completed 3D geological model fundamentally changed our understanding of Montauban and underscored the importance of securing control over the broader geological system,” noted Gordon Robb, ESGold’s CEO. “While we remain hyper-focused on advancing Montauban toward near-term production of our tailings project, we are moving exploration forward in tandem, recognizing the opportunity to create value on two tracks simultaneously,” he added (https://ibn.fm/bXFk9).

This development positions ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, particularly given modern exploration that has advanced beyond the historically mined footprint. Going forward, the company expects to significantly expand its ANT survey to cover approximately 70 square kilometers. The goal with this would be to assess the scale and continuity of the broader mineralized corridor.

“The addition of nearly 76 square kilometers of strategically positioned ground around Montauban is aimed at providing the scale necessary to properly evaluate the potential extent of the mineralized corridor identified by the model and to ensure we are not constrained by the historical boundaries as we systematically assess what Montauban may ultimately become,” Robb noted (https://ibn.fm/bXFk9).

ESGold also plans to integrate ANT results with existing geological, geochemical, and structural datasets for the property, along with developing a targeted step-out diamond-drilling program focused on testing high-priority targets identified by the model and expanded geophysics.

The expanded land position marks a critical inflection point for ESGold. The company is positioned to systematically evaluate the full potential of the emerging mineral system while not being constrained by its historical land base and boundaries. It is an opportunity for ESGold to redefine the scale of its historic mining camp, all while advancing towards production.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• The BayesShield AI system analyzed a full year of real retail trading data to validate the company’s machine learning models.
• BayesShield is designed to predict loss probability at the individual trade level and intervene before execution and is being trained on more than 11.7 billion historical trades using NVIDIA hardware.
• Perpetuals operates regulated derivatives infrastructure rather than a balance-sheet exchange, avoiding custody and counterparty exposure by design, and plans to deploy BayesShield across its regulated trading venues, including a CySEC-authorized MiFID II MTF.

Perpetuals.com (NASDAQ: PDC), a fintech company focused on AI-driven digital asset trading solutions and regulated market infrastructure, announced that it has completed a pilot of its BayesShield(TM) artificial intelligence system, indicating that the technology would have successfully filtered out 92% of losing retail trades in Bitcoin perpetual futures based on a year-long backtest of real trading activity (https://ibn.fm/Vbl3F).

The company reported that the BayesShield AI Pilot Program analyzed historical BTC-USD perpetual futures trades and identified patterns that predicted losses before execution. Chief Executive Patrick Gruhn said the findings validate years of research into retail trading behavior. “The data show that the vast majority of retail losses in leveraged derivatives markets are predictable and preventable,” Gruhn said in the statement. He added that BayesShield is intended to change how trading platforms manage retail risk by identifying high-probability losing trades before they reach the market.

The pilot comes amid volatile cryptocurrency conditions that have tested retail traders with sharp price swings. Perpetuals said BayesShield’s predictive models are designed to operate in real time, calculating win-loss probabilities using both individual trader profiles and aggregated market sentiment.

Perpetuals said it has begun full-scale development of BayesShield following the pilot. The production system is being trained on NVIDIA hardware using one of the largest retail trading datasets the company has assembled. That dataset includes more than 11.7 billion individual trades across multiple years, over one million unique user histories, cryptocurrency spot markets such as Bitcoin and Ethereum, crypto derivatives including perpetual futures and options, and selected traditional equity markets to support cross-asset validation.

According to the company, BayesShield is designed not only to protect retail participants but also to help product issuers, such as derivatives platforms and market makers, optimize hedging strategies by understanding loss probabilities before trades are executed.

Perpetuals said the system analyzes profit-and-loss profiles at the individual level while also modeling broader behavioral patterns across the market. “The retail derivatives market has historically operated on a model where the majority of participants lose money,” Gruhn said. “By predicting which trades are likely to fail before they execute, we can create trading environments that are both more ethical and more sustainable for all participants.”

Perpetuals has announced that BayesShield will be deployed across its regulated trading infrastructure, including a third-party, CySEC-authorized MiFID II MTF. A broader commercial rollout is planned for the second half of the year, with institutional partners and trading platforms invited to begin integration discussions.

Perpetuals.com operates as a regulated digital market infrastructure provider rather than a traditional exchange. The company offers an API-driven platform that enables brokers, institutions, and trading venues to access crypto and tokenized derivatives within compliant frameworks.

Unlike many offshore crypto venues, Perpetuals is structured to avoid custody of client assets and balance-sheet exposure, positioning itself as infrastructure rather than a trading counterparty. The platform is built around an EU Multilateral Trading Facility (“MTF”) framework and is designed to support crypto spot trading, perpetual futures, options, swaps, and tokenized structured products.

The company says this model addresses a structural gap in Europe, where regulatory constraints limit how brokers can offer leveraged crypto products, even as retail demand continues to grow. By providing regulated knock-out instruments and structured products, Perpetuals aims to offer leveraged exposure while remaining within European regulatory limits.

The company operates at the intersection of crypto derivatives, CFD brokerage infrastructure, and tokenized financial products. Industry data cited by Perpetuals show the global crypto perpetual futures market processing roughly $2.18 trillion in monthly volume, while Europe’s CFD market generates approximately $17.34 trillion in monthly notional volume.

European regulators restrict CFD brokers from offering high-leverage crypto products, creating a gap between trader demand and compliant access. Perpetuals is targeting that gap by providing regulated infrastructure that supports leveraged exposure without relying on offshore venues.

For more information, visit the company’s website at https://group.perpetuals.com.

NOTE TO INVESTORS: The latest news and updates relating to PDC are available in the company’s newsroom at https://ibn.fm/PDC

• One of the key advantages of photodynamic therapy is its selectivity.
• Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma.
• The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment.

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic mechanisms that aim to improve outcomes while minimizing systemic toxicity.

“Cancer therapy, especially for tumors near sensitive areas, demands precise treatment,” states a Frontier report on PDT, a treatment method leveraging photosensitizers (“PS”), specific wavelength light and oxygen to target cancer effectively. “Recent advancements affirm PDT’s efficacy, utilizing ROS generation to induce cancer cell death. With a history spanning over decades, PDT’s dynamic evolution has expanded its application across dermatology, oncology and dentistry.”

PDT is a treatment technique that combines a photosensitizing drug with a specific wavelength of light to produce reactive oxygen species that selectively destroy abnormal cells. According to the National Cancer Institute (“NCI”), PDT works by administering a photosensitizer that accumulates in cancer or diseased tissue and then activating it with light, causing a localized reaction that damages targeted cells while largely sparing surrounding healthy structures. This targeted approach distinguishes PDT from traditional systemic treatments such as chemotherapy, which circulate throughout the body and can produce widespread side effects.

One of the key advantages of photodynamic therapy is its selectivity. Because the therapy is activated only where light is applied, clinicians can limit damage to nearby healthy tissue, potentially reducing long-term toxicity compared with radiation or cytotoxic drugs. “When cells that have absorbed photosensitizers are exposed to a specific wavelength of light, the photosensitizer produces a form of oxygen, called an oxygen radical, that kills them,” explains NCI. “Photodynamic therapy may also damage blood vessels in the tumor, which prevents it from receiving the blood it needs to keep growing. And, it may trigger the immune system to attack tumor cells, even in other areas of the body.”

Despite these advantages, traditional photodynamic approaches have faced limitations related to photosensitizer chemistry, depth of light penetration and treatment protocols. Advances in drug design and light delivery systems are now helping overcome these challenges. Researchers are increasingly exploring photosensitizers that respond to visible light wavelengths rather than damaging ultraviolet radiation, which may offer safer activation profiles and improved tissue penetration. The development of more refined photodynamic platforms is expanding the potential clinical applications of this modality.

Within this evolving landscape, Soligenix is advancing HyBryte(TM), or SGX301, the company’s proprietary photodynamic therapy based on synthetic hypericin, designed for the treatment of early stage cutaneous T-cell lymphoma. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin and can significantly impact quality of life through persistent lesions, itching and chronic symptoms. According to the Cutaneous Lymphoma Foundation, CTCL often requires long-term management and treatment strategies that balance effectiveness with tolerability, particularly in early-stage disease. HyBryte aims to address this need by providing a targeted, nonsystemic therapy activated by safe visible light.

Unlike systemic treatments that circulate throughout the body, HyBryte involves topical application followed by controlled exposure to visible light, activating the drug locally in affected skin areas. HyBryte also leverages visible fluorescent or LED light activation rather than ultraviolet wavelengths, aligning with broader trends toward safer photodynamic strategies. This approach is designed to selectively destroy malignant cells while minimizing systemic exposure, potentially improving safety and tolerability compared with traditional therapies.

Soligenix has evaluated HyBryte in multiple clinical studies for CTCL, where photodynamic therapy offers a particularly appealing strategy due to the disease’s skin-focused nature. Late last year, the company achieved an important safety milestone in its confirmatory Phase 3 clinical trial of HyBryte for CTCL treatment. The company announced that its first Data Monitoring Committee meeting for its confirmatory Phase 3 study concluded that there are no safety concerns with the ongoing Phase 3 study and that HyBryte has an acceptable safety profile that remains consistent with the safety data from all prior clinical studies. 

Clinical development efforts have focused on demonstrating efficacy while maintaining quality of life, an important consideration given the chronic nature of CTCL and the potential side effects associated with systemic therapies such as chemotherapy or immunomodulators. The localized activation mechanism of photodynamic therapy allows repeated treatments with potentially fewer cumulative toxicities, making it an attractive alternative for long-term disease management.

Beyond oncology, Soligenix is also exploring the potential of HyBryte in psoriasis, a chronic inflammatory skin disease affecting millions worldwide. The expansion into additional dermatologic indications highlights the flexibility of photodynamic platforms, which can be adapted to target different pathological processes depending on the photosensitizer used and the treatment protocol. As research continues, photodynamic therapy may evolve into a versatile platform capable of addressing both malignant and nonmalignant inflammatory skin conditions.

The broader promise of photodynamic therapy lies in its ability to bridge precision medicine and targeted drug delivery. Rather than relying solely on molecular targeting or systemic exposure, PDT introduces a physical activation step through light, enabling clinicians to control where and when treatment occurs. As researchers refine photosensitizers and light delivery technologies, the therapy’s potential applications could expand further into deeper tumors, combination regimens and immune-modulating strategies.

Companies such as Soligenix are contributing to this exploration by advancing therapies that combine selective targeting with improved safety profiles, offering hope for patients who need effective options with fewer systemic burdens. From the laboratory to clinical practice, the continued development of light-activated therapies underscores the growing role of precision-focused approaches in the future of disease treatment.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Perpetuals.com focuses on 24/7, self-clearing trading venues that remove reliance on traditional clearing houses, representing an ethical alternative to questionable offshore exchanges and prediction markets.
• Proprietary machine learning tools are used to analyze risk and profit-and-loss probabilities at the trade level, with a dependable platform designed to comply with MiFID II and MiCA regulatory frameworks.
• The company’s Ledgera platform enables low-cost, cross-chain settlement with quantum-resilient security.

Perpetuals.com (NASDAQ: PDC), a fintech company focused on AI-driven digital asset trading solutions and regulated market infrastructure, is positioning itself at the intersection of traditional financial infrastructure and blockchain-based systems, targeting institutions that want exposure to digital assets without stepping outside regulated frameworks. The company develops software that allows regulated trading venues to operate continuously, with self-clearing and blockchain-native settlement replacing legacy post-trade processes.

Headquartered with operations across the United States, Europe, and Asia, Perpetuals.com is focused on financial market infrastructure rather than retail speculation. Its strategy reflects a broader shift among exchanges, brokers, and market operators that are seeking to modernize derivatives and crypto trading while remaining compliant with evolving regulatory regimes.

At the core of the company’s offering is infrastructure that removes the need for traditional clearing houses. By combining blockchain-based settlement with real-time risk assessment, Perpetuals aims to shorten settlement cycles and reduce counterparty exposure. The model is designed for markets that operate 24/7, a structural difference from legacy clearing systems built around limited trading hours.

Risk management plays a central role in this approach. Perpetuals uses proprietary machine learning models to analyze profit-and-loss probabilities at the individual trade level. According to the company, this enables exchanges and trading venues to design products with clearer risk parameters and stronger client protection, while also optimizing margining and capital efficiency.

The company’s technology stack is paired with blockchain infrastructure originally developed at EarlyWorks, the predecessor company whose assets were integrated into Perpetuals. EarlyWorks applied blockchain technology across a range of commercial use cases, including advertising verification, visitor management, and non-fungible token sales. Within Perpetuals, that blockchain experience has been repurposed for financial market settlement and custody.

One of the company’s flagship offerings is an AI-driven derivatives trading platform intended to modernize how derivatives are listed, traded, and settled. Rather than focusing on speculative leverage, the platform emphasizes transparency, continuous risk evaluation, and regulatory alignment. The company states that its systems are designed to comply with both MiFID II in Europe and the Markets in Crypto-Assets (“MiCA”) framework, which is shaping how digital asset services operate across the EU.

Beyond trading venues, Perpetuals has expanded into digital asset custody with its Quantum-Resilient Crypto Vaults, branded as Perpetuals.com Vaults. These vaults are designed as a self-custody solution for institutions that want to avoid reliance on third-party custodians or physical hardware wallets. The system combines infrastructure-level security with quantum-resilient cryptography, offering an alternative to audit-heavy or custodial models that introduce counterparty risk.

Management positions Perpetuals as an ethical alternative to offshore exchanges and prediction markets that operate outside regulatory oversight, for institutions and professional users that require legal certainty, predictable governance, and infrastructure that can integrate with existing financial systems.

This positioning reflects the backgrounds of the company’s leadership. Perpetuals was launched by executives with experience in European digital asset trading and market infrastructure, where regulatory scrutiny has been higher than in many offshore jurisdictions. That experience appears to inform the company’s emphasis on compliance-first design rather than retrofitting controls after the fact.

A practical illustration of this philosophy is Ledgera, a platform the company describes as a “meta blockchain” designed to sit above multiple Layer-1 networks. Ledgera functions as a Layer-2 settlement and abstraction layer, enabling transactions and asset movements across different blockchains without requiring users to interact directly with each underlying chain.

Ledgera is designed to combine quantum-resilient security with cross-chain interoperability. By abstracting Layer-1 complexity into a unified settlement engine, the platform aims to deliver high-speed transactions while maintaining sovereignty over assets. The company says this approach can reduce costs significantly compared with executing transactions directly on Layer-1 blockchains, where fees and congestion remain persistent challenges.

For institutional users, the appeal lies in unified control and cross-chain settlement without sacrificing compliance. Ledgera is intended to validate and coordinate activity across independent blockchains, allowing firms to settle trades, manage liquidity, or build fintech products without locking themselves into a single network. The company frames this as infrastructure that supports scale rather than experimentation.

Patrick Gruhn, CEO and founder of Perpetuals.com, has described Ledgera as an attempt to address what he sees as a structural tension in digital assets. “We designed Ledgera to solve the fundamental tension in digital assets: the tradeoff between speed and security, between decentralization and compliance. By abstracting Layer-1 complexity into a unified settlement engine, we’ve created infrastructure that’s fast enough for institutional trading, secure enough for self-custody, and flexible enough to span every chain that matters,” Gruhn said.

For more information, visit the company’s website at https://group.perpetuals.com.

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of mineral properties worldwide, just completed and delivered a comprehensive ANT-based 3D geological model for its Montauban Project
• The model illustrated mineralized architecture extending to depths of approximately 900 meters and 2 kilometres in length, with mineralized trends only bounded by the limits of existing ANT coverage
• It marks a pivotal milestone in the company’s evolution from a legacy mining site into a project with district-scale exploration potential
• Going forward, ESGold looks to validate the interpretations through expanded geophysics and targeted stepout drilling

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just marked a significant milestone with the completion and delivery of a comprehensive Ambient Noise Tomography (“ANT”)-based 3-dimensional (“3D”) geological model for its Montauban Project in Québec. Prepared by Geomatic World Inc. in collaboration with CAUR Technologies, this model marks a pivotal milestone in the company’s evolution from a legacy mining site into a project with district-scale exploration potential advancing in parallel with near-term tailings production in 2026.

“This is the most important technical milestone in ESGold’s history,” noted Gordon Robb, ESGold’s CEO. “The integrated 3D model has fundamentally changed how we understand Montauban. The scale indicated by this work is beyond what we had originally envisioned, and it reinforces our conviction that Montauban has the potential to evolve into a much larger mineral system,” he added (https://ibn.fm/4H5Mu).

The integrated ANT-based 3D model illustrated mineralized architecture extending to depths of approximately 900 meters. This is significantly deeper than any historical exploration at the Montauban property. Previously, most drilling was confined to depths of only 50 meters, with the deepest holes extending to approximately 250 meters. In addition, the model outlined approximately 2 kilometers of strike length within the current survey area, with mineralization appearing to widen at depth.

“The identification of deep-seated structural corridors, lithological continuity, and coincident geochemical anomalies in areas that have never been drilled is highly encouraging,” noted André Gauthier, Director of ESGold and the company’s senior consulting geologist. “From a geological perspective, the size and continuity suggested by this model point to a system with significant upside potential,” he added (https://ibn.fm/4H5Mu).

In addition to extending to depths never explored before, the model identified mineralized trends that remain open and are bounded by the limits of the existing ANT coverage. This pointed to the potential continuation beyond the current study area, further highlighting the property’s potential and the value it adds to ESGold and its operations.

ESGold aims to validate the interpretations through expanded geophysics and targeted drilling going forward, which will be a huge but integral undertaking for the company as it seeks to commercialize the property and generate value from it.

“The priority now is to validate these interpretations through expanded geophysics and targeted drilling. This level of structural continuity at depth is particularly notable given the complexity of Grenville-age terranes and helps explain why this system was not previously recognized,” noted Gauthier (https://ibn.fm/4H5Mu).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Safe Pro Group will present at the 2026 Defence Leaders Combat Engineer & Logistics Conference (“CEL26”), which takes place from February 10th to 12th.
• The presentation and conference allows the Safe Pro team to engage with potential international customers and collaborators including stakeholders from NATO, the U.S. Army, and Ukrainian defense forces.
• Safe Pro intends to highlight the company’s latest innovation, its proprietary Navigation, Observation & Detection Engine (“NODE”) hyper compute AI system.

Safe Pro Group Inc. (NASDAQ: SPAI), a developer of AI-powered defense and security solutions, is presenting at the 2026 Defence Leaders Combat Engineer & Logistics Conference (“CEL26”) in Krakow, Poland (https://ibn.fm/u4HK9).

This event, which takes place from February 10th to 12th, is one of Europe’s leading forums for military engineers and logistics collaboration, and it offers nations and organizations alike the tools and knowledge needed to improve both short-term preparedness and long-term design, as well as influence defense strategies and procurement policies.

At CEL26, Safe Pro team members will have the chance to engage and communicate with potential customers and collaborators including stakeholders from the U.S. Army, NATO, and Ukrainian defense forces. The company will also have the chance to reach representatives that are gathered to learn more about evolving technologies designed to deal with many of the challenges of the modern battlefield. 

During the presentation, Safe Pro plans to highlight the company’s latest innovation, its proprietary Navigation, Observation & Detection Engine (“NODE”) hyper compute AI system. This is an Edge-based, turnkey, and rapid field-deployable system for next-gen situational awareness and is built on Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”) platform.

The system provides both 2D and 3D interactive mapping and hazard detection, with real-time capabilities to allow field personnel and commanders to make informed mission plans, as well as better breach and resupply decisions when operating in challenging environments where communication is restricted or denied altogether.

The SPOTD platform uses AI to analyze both images and videos from drones to detect and identify more than 150 small explosive threats. It converts raw data into high-resolution outputs to help improve decision-making in defense, security, and humanitarian missions. The platform has been deployed in operational environments in Ukraine for almost three years and has a dataset of more than 2.4 million analyzed images. It has also identified over 40,000 threats and has coverage of around 28,000 acres.

Speaking about the upcoming presentation, Safe Pro Group Chairman and CEO, Dan Erdberg, said “Presenting at CEL26 is a unique opportunity to engage with the international stakeholders including representatives of the U.S. Army, NATO and allied defense forces, allowing us to reinforce the role that our AI technology can have on the future of military engineering and maneuver forces.” He also added that “Through development of novel solutions like our edge-based NODE for real time battlefield analysis, we are seeking to provide today’s combat engineers with the tools and capabilities to enhance force protection of maneuver support missions.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that specializes in developing and delivering AI-powered defense and security solutions, such as drone services and ballistic protective gear. It serves customers in a variety of industries including homeland security, defense, humanitarian, law enforcement, and others. Safe Pro has the vision of leading the evolution of security and threat detection and wants to empower governments and organizations with the tools needed to respond to evolving threats.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system
• This system provides several advantages over technologies that are currently available for treating tumors with proton therapy
• The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers.

Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy.

According to Professor Steve Myers, the former Director of Accelerators and Technology at CERN (European Organization for Nuclear Research): “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. “

Liora’s LiGHT System is installed at the Science and Technology Facilities Council’s (“STFC”) Daresbury Laboratory, where it has already achieved 230 MeV proton beam energy, a critical validation milestone that places the platform on par with, and potentially ahead of, incumbent proton therapy systems.

Speaking about the acquisition of Liora, LIXTE CEO Geordan Pursglove said that “The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies.” He also added that “We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.” 

Pursglove also states that the addition of Liora represents an excellent complement to the pharmaceutical side of the business, particularly LIXTE’s ongoing clinical trials with LB-100, the company’s lead clinical candidate. LiGHT’s ability to deliver higher, more precise radiation doses creates potential synergy with radiosensitizers while its software-controlled energy delivery enables personalized treatment, aligning well with combination-therapy strategies.

LB-100 is designed to enhance the activity of chemotherapy and immunotherapy and has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by over 25 preclinical and translational studies.

It’s currently being evaluated in multiple programs that are targeting solid tumors that only have limited treatment options.

The ongoing trials and studies are being done in collaboration with leading academic cancer centers and partners and include combining LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combining it with chemotherapy in advanced soft tissue sarcoma.

About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies. Rather than standalone treatments, the company focuses on advancing an approach to boost the effectiveness of established therapies and addressing challenges. Alongside internal development, the company has also taken strategic action to extend capabilities beyond developing drugs.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• Nevada Organic Phosphate Inc. presented at the Metals Investor Forum in January 2026, outlining its plan to explore for and develop a significant organic P205 resource, in northeast Nevada, to supply raw, organic phosphate directly to farmers.
• The company’s Murdock Mountain project in Nevada has confirmed trace to no heavy-metal content, supporting its potential use in certified organic agriculture, with drill results pointing to phosphate grades of roughly 10%–12% P₂O₅ with strong lateral continuity.
• The company believes its Nevada deposits could support a resource in the range of 200 million tonnes, and the site’s location near Union Pacific rail infrastructure may simplify logistics for direct-ship fertilizer distribution.
• Analyst and shareholder John Kaiser examined how a scalable supply of organic phosphate could enable growth in organic farming.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, participated in the Metals Investor Forum in January 2026, where it highlighted its position as a significant potential producer of raw, organic, direct-ship pit-run phosphate fertilizer aimed at the expanding organic farming market. The Vancouver-based company used the forum to outline progress at its Murdock Mountain Property in Elko County, Nevada, and to discuss how a scalable supply of organic phosphate could address a key constraint facing organic agriculture: access to fertilizer inputs that meet organic certification standards.

Investor attention has been sharpened by a recent analysis published by Kaiser Research Substack, in which Nevada Organic Phosphate shareholder John Kaiser explored the question, “What would a scalable supply of organic phosphate do for the growth of organic farming and what would that be worth?” (https://ibn.fm/R8FAX).

Kaiser’s analysis frames Nevada Organic Phosphate as distinct from many junior mining stories tied to geopolitical supply chains. Instead, he positions NOP as linked to domestic food systems and organic agriculture. He also notes that the company’s shares experienced increased activity in January following release of drill results. 

NOP recently completed an initial six-hole drill program at Murdock Mountain after receiving a long-awaited Bureau of Land Management permit in late 2025. The program confirmed phosphate grades in the 10%–12% P₂O₅ range and demonstrated lateral continuity of the mineralized beds.

More significant for organic agriculture, according to Kaiser’s analysis, was confirmation that heavy metal content in fresh bedrock remains below U.S. Department of Agriculture thresholds for organic field application. This addressed a central uncertainty: whether low heavy-metal levels observed in surface outcrops would persist at depth. The results suggest that the broader phosphate beds beneath the Leach Mountain Range may share similar characteristics, supporting NOP’s view that it could ultimately delineate a resource on the order of 200 million tonnes suitable for direct application as ground rock fertilizer.

Phosphate is essential for crop growth, with roughly 90% of global supply used in agriculture. Most commercial phosphate comes from higher-grade sedimentary deposits that require chemical processing to remove heavy metals. The resulting products, such as monoammonium phosphate (“MAP”) and di-ammonium phosphate (“DAP”), do not qualify as organic.

Organic farmers instead rely on bone meal and manure-based inputs, which are by-products of livestock production and cannot scale easily with rising demand for organic food. Kaiser notes that while a scalable supply of organic phosphate alone would not guarantee expansion of organic agriculture, it represents a critical enabling input.

USDA data from 2022 show organic farm output at about $9 billion, compared with more than $200 billion for conventional agriculture. Demand for organic fruits, vegetables, eggs, and dairy continues to outpace supply in many regions, raising questions about how fertilizer inputs could keep pace. NOP is targeting this gap with a whole-rock product that can be applied directly to fields and is designed to work with soil biology over longer timeframes.

The Murdock Mountain project benefits from proximity to Union Pacific rail infrastructure near Montello, Nevada, which could support bulk transport of ground phosphate to agricultural markets. The company’s production model is based on shallow sedimentary beds that may allow relatively straightforward extraction, followed by grinding, bagging, and shipment. NOP says its approach avoids the need for chemical beneficiation, which typically adds cost and environmental complexity.

Exploration targets across the expanded project area now cover more than 7,800 acres. Company disclosures cite an Exploration Target Mineralization Inventory ranging from 10 to 46 million tonnes on the initial application area, with broader potential across new lease-application ground reaching 200–220 million tonnes. NOP expects to continue delineation work through 2026, with certification and agronomic testing planned to evaluate suitability across different soil types and crops.

NOP’s strategy centers on direct application of reactive rock phosphate rather than competing with conventional chemical fertilizer producers. The company says its product is intended to support regenerative farming practices by working with natural soil bacteria and promoting longer-term nutrient availability.

While still at an early stage, Nevada Organic Phosphate is positioning its Nevada assets as a potential alternative source of organic-certified phosphate at scale, an input that many observers see as necessary if organic agriculture is to expand beyond its current footprint.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOPFF are available in the company’s newsroom at https://ibn.fm/NOP